Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease

Pancreas

Volumn 39, Issue 8, 2010, Pages 1185-1190

  Van Geenen, Erwin Jan M ^a,b   Smits, Mark M ^a   Schreuder, Tim C M A ^a   Van Der Peet, Donald L ^a   Bloemena, Elisabeth ^a   Mulder, Chris J J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

BMI; NAFLD; NAFPD; NASH; PL

Indexed keywords

FAT;

AGED; ALCOHOL ABUSE; ARTICLE; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIPOMATOSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PANCREAS DISEASE; PANCREATIC STEATOSIS; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; AUTOPSY; FATS; FATTY LIVER; FEMALE; HUMANS; LIPOMATOSIS; LIVER; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC DISEASES; RETROSPECTIVE STUDIES;

EID: 77958576631     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181f6fce2     Document Type: Article

References (42)

1. Ogden CL, Yanovski SZ, Carroll MD, et al. The epidemiology of obesity. Gastroenterology. 2007;132(6):2087Y2102.
2. OECD Health Data 2008VFrequently Requested Data. http://www.oecd.org/10- 12-2008. Available at: http://www.oecd.org/document/16/0,2340,en-2649-34631- 2085200-1-1-1-1,00.html.
3. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625Y1638.
4. Wilson PW, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162(16):1867Y1872.
5. van Herpen NA, Schrauwen-Hinderling VB. Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol Behav. 2008;94(2): 231Y241.
6. Ogilvie R. The island of Langerhans in 19 cases of obesity. J Pathol. 1933;37:473Y481.
7. Olsen TS. Lipomatosis of the pancreas in autopsy material and its relation to age and overweight. Acta Pathol Microbiol Scand A. 1978;86A(5):367Y373.
8. Stamm BH. Incidence and diagnostic significance of minor pathologic changes in the adult pancreas at autopsy: a systematic study of 112 autopsies in patients without known pancreatic disease. Hum Pathol. 1984;15(7):677Y683.
9. Tushuizen ME, Bunck MC, Pouwels PJ, et al. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes Care. 2007;30(11):2916Y2921.
10. Saisho Y, Butler AE, Meier JJ, et al. Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. Clin Anat. 2007;20(8):933Y942.
11. Bresson JL, Schmitz J, Saudubray JM, et al. [Johanson-Blizzard's syndrome: another cause of pancreatic lipomatosis (author's transl)]. Arch Fr Pediatr. 1980;37(1):21Y24.
12. Feigelson J, Pecau Y, Poquet M, et al. Imaging changes in the pancreas in cystic fibrosis: a retrospective evaluation of 55 cases seen over a period of 9 years. J Pediatr Gastroenterol Nutr. 2000;30(2):145Y151.
13. Lacaille F, Mani TM, Brunelle F, et al. Magnetic resonance imaging for diagnosis of Shwachman's syndrome. J Pediatr Gastroenterol Nutr. 1996;23(5):599Y603.
14. Walters MN. Adipose atrophy of the exocrine pancreas. J Pathol Bacteriol. 1966;92(2):547Y557.
15. Mathur A, Pitt HA, Marine M, et al. Fatty pancreas: a factor in postoperative pancreatic fistula. Ann Surg. 2007;246(6):1058Y1064.
16. Mathur A, Zyromski NJ, Pitt HA, et al. Pancreatic steatosis promotes dissemination and lethality of pancreatic cancer. J Am Coll Surg. 2009;208(5):989Y994.
17. Musso G, Gambino R, Bo S, et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care. 2008;31(3):562Y568.
18. Rector RS, Thyfault JP, Wei Y, et al. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol. 2008; 14(2):185Y192.
19. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25(8):883Y889.
20. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology. 2005;129(1):375Y378.
21. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865Y873.
22. Mathur A, Marine M, Lu D, et al. Nonalcoholic fatty pancreas disease. HPB (Oxford ). 2007;9(4):312Y318.
23. Pitt HA. Hepato-pancreato-biliary fat: the good, the bad and the ugly. HPB (Oxford ). 2007;9(2):92Y97.
24. Kleiner DE, Brunt EM, Van NM, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313Y1321.
25. Schreuder TC, Verwer BJ, van Nieuwkerk CM, et al. Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol. 2008;14(16): 2474Y2486.
26. Schwenzer NF, Machann J, Martirosian P, et al. Quantification of pancreatic lipomatosis and liver steatosis by MRI: comparison of in/opposed-phase and spectral-spatial excitation techniques. Invest Radiol. 2008;43(5):330Y337.
27. Burt AD. Steatosis and steatohepatitis. Curr Diagn Pathol. 2001;7:141Y147.
28. Yki-Jarvinen H, Ryysy L, Kauppila M, et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82(12):4037Y4043.
29. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40(suppl 1):S17YS29.
30. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf ). 2006;64(4):355Y365.
31. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95(5):2409Y2415.
32. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132(6):2169Y2180.
33. Vettor R, Milan G, Rossato M, et al. Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther. 2005;22(suppl 2):3Y10.
34. Smith SR, Lovejoy JC, Greenway F, et al. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism. 2001;50(4):425Y435.
35. Nielsen S, Guo Z, Johnson CM, et al. Splanchnic lipolysis in human obesity. J Clin Invest. 2004;113(11):1582Y1588.
36. Miyazaki Y, Glass L, Triplitt C, et al. Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. 2002;283(6):E1135YE1143.
37. Clark JB, Palmer CJ, Shaw WN. The diabetic Zucker fatty rat. Proc Soc Exp Biol Med. 1983;173(1):68Y75.
38. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 2002;51(1):7Y18.
39. Peterson R, Shaw W, Neel M, et al. Zucker diabetic fatty rat as a model for nonYinsulin-dependent diabetes mellitus. ILAR. 1990; 32(3):16Y19.
40. Matsui J, Terauchi Y, Kubota N, et al. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferatorYactivated receptor-gammaYdeficient mice on a high-fat diet. Diabetes. 2004; 53(11):2844Y2854.
41. Szendroedi J, Roden M. Ectopic lipids and organ function. Curr Opin Lipidol. 2009;20(1):50Y56.
42. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005; 128(7):1898Y1906.